P1231: ZILOVERTAMAB VEDOTIN (MK-2140) FOR THE TREATMENT OF NON-HODGKIN LYMPHOMA: THE PHASE 1 DOSE ESCALATION AND COHORT EXPANSION WAVELINE-001 STUDY OF AN ANTI-ROR1 ANTIBODY-DRUG CONJUGATE

P1231: ZILOVERTAMAB VEDOTIN (MK-2140) FOR THE TREATMENT OF NON-HODGKIN LYMPHOMA: THE PHASE 1 DOSE ESCALATION AND COHORT EXPANSION WAVELINE-001 STUDY OF AN ANTI-ROR1 ANTIBODY-DRUG CONJUGATE

Bibliographic Details
Main Authors:	M. Wang, M. Mei, P. M. Barr, J. Barrientos, S. de Vos, R. Furman, K. Patel, P. A. Thompson, M. Choi, A. Kallam, Y. Zhu, S. Chakraborty, P. Marinello, S. E. Spurgeon
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000847788.96420.63

Similar Items

P1200: ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED OR REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL): UPDATED RESULTS FROM THE PHASE 1 WAVELINE-001 STUDY
by: Stephen Spurgeon, et al.
Published: (2023-08-01)

P1144: PHASE 2 WAVELINE-004 STUDY: ZILOVERTAMAB VEDOTIN (MK-2140) IN RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)
by: Muhit Ozcan, et al.
Published: (2023-08-01)

The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the Proliferation of Ovarian and Endometrial Cancer Cells
by: Dongli Liu, et al.
Published: (2022-04-01)

2140
by: Pinaki Sarder, et al.
Published: (2017-09-01)

P1435: PRECLINICAL EVALUATION OF ZILOVERTAMAB-BASED ANTI-ROR1 CHIMERIC ANTIGEN RECEPTORS IN NK AND T CELLS
by: S. Meinke, et al.
Published: (2022-06-01)

A novel approach to deep venous arterialization using WavelinQ EndoAVF technology
by: Olivia K. Pickering, BA (Comms), MD, et al.
Published: (2024-06-01)

Strategies of Cognitive Estrangement in Kim Stanley Robinson’s New York 2140
by: Klata Michał
Published: (2021-07-01)

PB2140: EVALUATION OF EARLY RELAPSE IN MULTIPLE MYELOMA (MM) PATIENTS
by: Annita-Ioanna Gkioka, et al.
Published: (2023-08-01)

2.14 / 2.140 Analysis and Design of Feedback Control Systems, Spring 2007
by: Trumper, David
Published: (2007)

Las cuentas de la colonización feudal (Mallorca, 1231 - 1245)
by: Pau Cateura Benasser
Published: (1997-01-01)

A NICER View of PSR J1231−1411: A Complex Case
by: Tuomo Salmi, et al.
Published: (2024-01-01)

2140 Time-resolved contrast-enhanced whole-heart coronary MRA using 3DPR
by: Jerecic Renate, et al.
Published: (2008-10-01)

Emergency preparedness for mass gatherings: Lessons of “12.31” stampede in Shanghai Bund
by: Yong-He Dong, et al.
Published: (2017-08-01)

Brentuximab vedotin induced uveitis
by: Stijn Therssen, M.D., et al.
Published: (2022-06-01)

ROR1 and ROR2 in Human Malignancies: Potentials for Targeted Therapy
by: Guilly eRebagay, et al.
Published: (2012-04-01)

PSR J1231–1411 Revisited: Pulse Profile Analysis of X-Ray Observation
by: Liqiang Qi, et al.
Published: (2025-01-01)

A phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
by: Rebecca A. Shatsky, et al.
Published: (2024-02-01)

Immunoprecipitation of ROR1
by: Vincent Bicocca, et al.
Published: (2013-09-01)

NOTCH3 p.Arg1231Cys is markedly enriched in South Asians and associated with stroke
by: Juan Lorenzo Rodriguez-Flores, et al.
Published: (2024-09-01)

Grzech przeciwko Duchowi Świętemu (Mt 12,31-32) w "De principiis" Orygenesa
by: Waldemar Turek
Published: (1997-12-01)

Correction: a phase 1b study of zilovertamab in combination with paclitaxel for locally advanced/unresectable or metastatic HER2-negative breast cancer
by: Rebecca A. Shatsky, et al.
Published: (2024-03-01)

Variant Transcript of ROR1 ENST00000545203 Does Not Encode ROR1 Protein
by: Jie Xian, et al.
Published: (2024-07-01)

Pan-Tissue and -Cancer Analysis of ROR1 and ROR2 Transcript Variants Identify Novel Functional Significance for an Alternative Splice Variant of ROR1
by: Miya John, et al.
Published: (2022-10-01)

ROR1 Flow Cytometry
by: Vincent Bicocca, et al.
Published: (2013-09-01)

ROR: Nuclear Receptor for Melatonin or Not?
by: Haozhen Ma, et al.
Published: (2021-05-01)

NuSTAR Hard X-Ray Monitoring of Gravitationally Lensed Quasar RX J1131–1231
by: Cora A. DeFrancesco, et al.
Published: (2023-01-01)

SIRT1 Activator E1231 Alleviates Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism
by: Jiangxue Han, et al.
Published: (2023-06-01)

بدیعیة الشاعر عبدالله بن محمد أمین المفتی الموصلی (ت 1231هـ/ 1817م)
by: عبدالله المولى
Published: (2008-03-01)

The application of machine learning methods to the prediction of novel ligands for RORγ/RORγT receptors
by: Rafał A. Bachorz, et al.
Published: (2023-01-01)

Correction to: Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer
by: C. E. Henry, et al.
Published: (2022-06-01)

الشاعر الحسيني هاشم الكعبي (ت 1231هـ / 1816م) وقصيدته المقصورة (دراسة موضوعية فنية)
by: Syed Alireza Khawajapur, et al.
Published: (2022-03-01)

PB2140: ALLOGENEIC STEM CELL TRANSPLANTATION IN RARE T-NHL SUBTYPES: FOCUS ON AITL, MF/SS, HSTCL. A SINGLE BMT-UNIT EXPERIENCE.
by: T. Tzenou, et al.
Published: (2022-06-01)

A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors
by: Hans Gelderblom, et al.
Published: (2020-05-01)

A multicenter, phase 1, dose escalation clinical trial (G-FORCE-1) of XRT, RRx-001 and temozolomide followed by temozolomide +/- RRx-001 in newly diagnosed glioblastoma
by: Howard Fine, et al.
Published: (2023-06-01)

Perppu Pengawasan Hakim Mk Versus Putusan Final Mk
by: Malik Malik
Published: (2016-05-01)

The Emerging Roles of Long Noncoding RNA ROR (lincRNA-ROR) and its Possible Mechanisms in Human Cancers
by: Yan Pan, et al.
Published: (2016-11-01)

Distinct Patterns of Stromal and Tumor Expression of ROR1 and ROR2 in Histological Subtypes of Epithelial Ovarian Cancer
by: C.E. Henry, et al.
Published: (2017-06-01)

1389 An assessment of ROR1 expression across tumor tissue and the investigation of a ROR1-targeted T cell engager as a therapeutic strategy to target ROR1 positive tumors
by: Daniel Snell, et al.
Published: (2023-11-01)

Cerebellum and neurodevelopmental disorders: RORα is a unifying force
by: Svethna Ribeiro, et al.
Published: (2023-03-01)

Brentuximab vedotin (Adcetris®) in therapy of system anaplastic large cell lymphoma. Case report
by: A. A. Semenova, et al.
Published: (2019-01-01)